Back to Trials
NCT06446661NARecruiting

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

University of Chicago

Start Date

5/19/2026

Completion Date

6/15/2028

Summary

This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.

Detailed Description

The study will begin with a 28-day pilot phase where participants will be asked to complete questionnaires to determine if the text message intervention is acceptable to participants. In the efficacy phase, the study will compare adherence to oral mercaptopurine and methotrexate between those who receive the high intensity text message intervention and those who receive standard-of-care. It is believed that high-intensity text messages will increase patient adherence within cycle 1.

Eligibility Criteria

Age Range: 15 years to No maximum

Inclusion Criteria: * Age of 15 years or older at time of enrollment * Diagnosed with ALL or T-cell lymphoblastic lymphoma * Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention. Exclusion Criteria: * Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages * Patient does not wish to participate * Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.

Interventions

OTHER

High Intensity

OTHER

No Text Messagings

OTHER

Low Intensity Text Messaging

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma

Locations

University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois 60637

United States